JP2013540713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540713A5 JP2013540713A5 JP2013526475A JP2013526475A JP2013540713A5 JP 2013540713 A5 JP2013540713 A5 JP 2013540713A5 JP 2013526475 A JP2013526475 A JP 2013526475A JP 2013526475 A JP2013526475 A JP 2013526475A JP 2013540713 A5 JP2013540713 A5 JP 2013540713A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- chal
- alkyl
- compound
- hydrocarbon group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- -1 X is CN Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000001258 synovial membrane Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1014633.0A GB201014633D0 (en) | 2010-09-02 | 2010-09-02 | Rheumatoid arthritis treatment |
| GB1014633.0 | 2010-09-02 | ||
| PCT/EP2011/065123 WO2012028688A1 (en) | 2010-09-02 | 2011-09-01 | Rheumatoid arthritis treatment using polyunsaturated long chain ketones |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016216524A Division JP2017075148A (ja) | 2010-09-02 | 2016-11-04 | ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540713A JP2013540713A (ja) | 2013-11-07 |
| JP2013540713A5 true JP2013540713A5 (enExample) | 2016-05-12 |
| JP6082347B2 JP6082347B2 (ja) | 2017-02-15 |
Family
ID=43013608
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526475A Expired - Fee Related JP6082347B2 (ja) | 2010-09-02 | 2011-09-01 | ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療 |
| JP2016216524A Withdrawn JP2017075148A (ja) | 2010-09-02 | 2016-11-04 | ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016216524A Withdrawn JP2017075148A (ja) | 2010-09-02 | 2016-11-04 | ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9682930B2 (enExample) |
| EP (1) | EP2611432A1 (enExample) |
| JP (2) | JP6082347B2 (enExample) |
| KR (1) | KR20130112880A (enExample) |
| CN (2) | CN109893518A (enExample) |
| AU (1) | AU2011298340B2 (enExample) |
| CA (1) | CA2810102A1 (enExample) |
| GB (1) | GB201014633D0 (enExample) |
| IL (1) | IL224963A (enExample) |
| WO (1) | WO2012028688A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| GB201205394D0 (en) | 2012-03-27 | 2012-05-09 | Adlens Ltd | Improvements in or relating to deformable non-round membrane assemblies |
| GB201221329D0 (en) | 2012-11-27 | 2013-01-09 | Avexxin As | Dermatitis treatment |
| GB201313238D0 (en) | 2013-07-24 | 2013-09-04 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
| GB201409363D0 (en) * | 2014-05-27 | 2014-07-09 | Avexxin As | Skin cancer treatment |
| GB201501144D0 (en) | 2015-01-23 | 2015-03-11 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| CA3037582A1 (en) | 2016-09-21 | 2018-03-29 | Avexxin As | Pharmaceutical composition |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| JP7305562B2 (ja) * | 2017-06-16 | 2023-07-10 | アヴェクシン エーエス | 線維性疾患の治療のための組成物および方法 |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| GB201910644D0 (en) | 2019-07-25 | 2019-09-11 | Coegin Pharma As | Cancer Treatment |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US20210311022A1 (en) * | 2020-03-27 | 2021-10-07 | Organogenesis, Inc. | Methods, kits and compositions for characterizing an anti-inflammatory response of a product |
| US12582622B2 (en) | 2020-10-08 | 2026-03-24 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| IL305969A (en) * | 2021-03-23 | 2023-11-01 | Organogenesis Inc | Methods kits and compositions for characterizing an anti-inflammatory response of a product |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN121038779A (zh) | 2023-02-03 | 2025-11-28 | 特瑞斯制药公司 | 每晚一次的低钠羟丁酸盐组合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670465A (en) * | 1986-05-21 | 1987-06-02 | Syntex (U.S.A.) Inc. | Arachidonic acid analogs |
| JPH0987176A (ja) | 1995-09-26 | 1997-03-31 | Shiseido Co Ltd | 糸球体腎炎抑制剤 |
| JPH09268153A (ja) | 1996-04-02 | 1997-10-14 | Sagami Chem Res Center | トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤 |
| US6262119B1 (en) * | 1996-04-12 | 2001-07-17 | Peptide Technology Limited | Methods of treating immunopathologies using polyunsaturated fatty acids |
| EP1140791A2 (en) | 1997-09-23 | 2001-10-10 | Bristol-Myers Squibb Company | Selective cpla 2 inhibitors |
| US6107334A (en) | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| US7605149B1 (en) | 1998-07-13 | 2009-10-20 | University Of South Florida | Modulation of the phospholipase A2 pathway as a therapeutic |
| US6031014A (en) | 1998-12-08 | 2000-02-29 | Crivello; James V. | Initiator compositions and methods for their synthesis and use |
| DE60032774D1 (de) | 1999-07-19 | 2007-02-15 | Lilly Co Eli | Spla2 inhibitoren |
| WO2002060535A1 (en) * | 2001-01-31 | 2002-08-08 | Leff Alan R | Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2? |
| EP1243524A3 (en) | 2001-03-16 | 2004-04-07 | Pfizer Products Inc. | Pharmaceutical kit for oxygen-sensitive drugs |
| US7101875B2 (en) * | 2001-12-03 | 2006-09-05 | Wyeth | Methods for treating arthritic disorders |
| GB0202002D0 (en) * | 2002-01-29 | 2002-03-13 | Leiv Eiriksson Nyotek A S | Use |
| MY131170A (en) | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
| US20040111957A1 (en) | 2002-12-13 | 2004-06-17 | Filippini Brian B. | Water blended fuel composition |
| WO2006106438A2 (en) * | 2005-01-11 | 2006-10-12 | Evolva Sa | Modulators of ppar activity |
| US20060246115A1 (en) * | 2005-03-04 | 2006-11-02 | Ricardo Rueda | Nutritional products for ameliorating symptoms of rheumatoid arthritis |
| EP2114397A4 (en) | 2006-12-20 | 2013-06-12 | Medwell Lab Ltd | NEW CONJUGATES OF MULTIPLE UNSATURATED FATTY ACIDS WITH AMINES AND ITS THERAPEUTIC USES |
| NZ552238A (en) | 2006-12-20 | 2009-07-31 | Seperex Nutritionals Ltd | An extract |
| EP2207543A2 (en) * | 2007-09-14 | 2010-07-21 | Resolvyx Pharmaceuticals, Inc. | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function |
| WO2009061208A1 (en) | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
| EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| KR101783817B1 (ko) * | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| GB0909643D0 (en) * | 2009-06-04 | 2009-07-22 | Avexxin As | Glomerulonephritis treatment |
| WO2011097276A1 (en) * | 2010-02-02 | 2011-08-11 | Martek Biosciences Corporation | Methods and compositions for treating arthritis with docosahexaenoic acid |
-
2010
- 2010-09-02 GB GBGB1014633.0A patent/GB201014633D0/en not_active Ceased
-
2011
- 2011-09-01 KR KR1020137008287A patent/KR20130112880A/ko not_active Abandoned
- 2011-09-01 CA CA2810102A patent/CA2810102A1/en not_active Abandoned
- 2011-09-01 CN CN201811592300.8A patent/CN109893518A/zh active Pending
- 2011-09-01 WO PCT/EP2011/065123 patent/WO2012028688A1/en not_active Ceased
- 2011-09-01 JP JP2013526475A patent/JP6082347B2/ja not_active Expired - Fee Related
- 2011-09-01 CN CN2011800520405A patent/CN103249408A/zh active Pending
- 2011-09-01 AU AU2011298340A patent/AU2011298340B2/en not_active Ceased
- 2011-09-01 EP EP11757227.1A patent/EP2611432A1/en not_active Ceased
-
2013
- 2013-02-27 IL IL224963A patent/IL224963A/en active IP Right Grant
- 2013-03-01 US US13/783,088 patent/US9682930B2/en not_active Expired - Fee Related
-
2016
- 2016-11-04 JP JP2016216524A patent/JP2017075148A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503797A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2014508753A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| MX2009005398A (es) | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. | |
| EA201490552A1 (ru) | Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью | |
| EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
| MA32812B1 (fr) | Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale | |
| JP2014511891A5 (enExample) | ||
| JP2016516020A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| JP2016040288A5 (enExample) | ||
| EA200601897A1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина | |
| EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| JP2015505296A5 (enExample) | ||
| EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| JP2010155827A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| JP2016510785A5 (enExample) |